Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ironwood Pharmaceuticals Inc IRWD

Healthcare Biotechnology
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of... see more

Recent & Breaking News (NDAQ:IRWD)

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 20, 2024

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 19, 2024

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 18, 2024

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 17, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 16, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 15, 2024

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Business Wire May 9, 2024

Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference

Business Wire May 6, 2024

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

Business Wire May 1, 2024

Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call

Business Wire April 25, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire April 8, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire April 5, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire April 1, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 30, 2024

Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Business Wire March 28, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 28, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 27, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 26, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 25, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 24, 2024